Humacyte Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess

 - Results published in Oxford Academic’s Military Medicine Journal -

- After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency -

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication in Oxford Academic’s Military Medicine of positive long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine. The publication, titled "Evaluating the Safety and Efficacy of Humacyte Acellular Tissue-Engineered Vessel in a Real-World Combat Setting: A Retrospective Observational Multicenter Study,” reported that trauma patients with wartime injuries treated with Symvess were observed to have a continued high rate of patency (87.1%), 100% limb salvage, and zero cases of conduit infection in 17 patients with extremity injuries followed for up to 18 months.

“War is changing, and our military medicine needs to keep pace,” said Oleksandr Sokolov, M.D., Ph.D., a Ukrainian vascular surgeon who treated patients with Symvess under the humanitarian program. “With the growing scale and complexity of missile- and drone-related trauma, prolonged delays and infection risk amplify the medical challenge, exposing critical gaps in timely treatment and long-term recovery. Immediate availability of a biologic conduit enables faster reconstruction and offers a practical alternative even when autologous vein is not feasible. Long-term outcomes reinforce my conclusion from using Symvess: Biologic conduits hold strong potential to advance vascular trauma care by shortening reconstruction time, reducing acute ischemia duration, lowering complication rates, and improving limb salvage.”

Battlefield vascular injuries are some of the most difficult for surgeons to treat because of time pressure and the potential for infection. Unlike traditional autologous vein grafts, which require harvesting a patient’s vein during surgery, Symvess (acellular tissue engineered vessel (ATEV™)) is designed to be immediately available off-the-shelf — saving critical surgical time in wartime situations. Symvess has also showed low rates of infection.

The publication described the outcomes of 17 patients treated with treated with Symvess whose injuries included combat-related extremity vascular trauma from gunshots, blasts, and shrapnel. At 30 days of follow up, the primary measurement point in the study, patients treated with Symvess had incurred zero deaths, zero amputations, and zero cases of infection. The 30-day primary and secondary patency rate was 93.8%. The long-term results published for the first time in Military Medicine confirmed these earlier positive outcomes. At up to 18 months of follow up, patients were observed to have suffered zero deaths, zero infections, and zero amputations. Furthermore, Symvess demonstrated continued high levels of patency (87.1%) and no instances of immunological rejection.

https://finance.yahoo.com/news/humacyte-announces-publication-long-term-120000366.html

Government collapse triggers French equities' steepest fall in over a month

 European stocks recouped their losses on Monday after the fall triggered by the unexpected resignation of French Prime Minister Sebastien Lecornu was offset by a rally in semiconductor stocks following AMD's chip supply deal with OpenAI.

The pan-European STOXX 600 closed flat. The index briefly hit an intraday record high on Monday after climbing more than 2.8% last week.

French stocks tumbled 1.4%, marking their steepest one-day drop since August and snapping a six-day winning streak, after Lecornu abruptly resigned just hours after unveiling his new cabinet.

French bond yields spiked, with the 10-year note hitting a one-week high, while the euro weakened.

LUXURY STOCKS AND BANKS TAKE HIT

Investors remain wary of France's fiscal health, as the country holds the euro zone’s largest budget deficit - nearly double the EU's 3% threshold.

French luxury stocks took a hit, with LVMH, EssilorLuxottica, and Hermes sliding over 2.3% each.

Banks also bore the brunt, with SocGen and BNP Paribas plunging 3.2% and 4.2% respectively.

Mid-cap French stocks fell 1.7%.

Political instability has plagued France since President Emmanuel Macron's 2022 re-election, with no party commanding a parliamentary majority.

"The political turmoil in France isn't new. It's just another confirmation of the fragility within the political system in France and how hard it is for them to be able to maintain a government," said Daniela Hathorn, senior market analyst at Capital.com.

French blue-chips have lagged European peers so far this year, up over 7% compared to double-digit gains seen in most developed countries.

On the European markets more broadly, oil and gas gained 1.3% tracking higher oil prices after OPEC+'s planned production increase for November was more modest than expected.

European semiconductor companies rose after AMD's chip supply deal with OpenAI. BESI jumped 12.4% while ASML rose 2%.

Wall Street brokerage JPMorgan upgraded its stance on the euro zone to "overweight" from "neutral", noting that the equities in the region have become more attractive after several months of underperformance and policy support.

Among other moving stocks, SEB slid 21.4% after the French kitchenware maker cut its annual sales and profit forecast.

Mondi dropped 16% after the British packaging and paper firm said its core profit growth slowed in the third quarter due to weak demand and lower prices.

https://www.msn.com/en-us/money/markets/government-collapse-triggers-french-equities-steepest-fall-in-over-a-month/ar-AA1NXNDC

Trump imposing new 25% large truck tariff starting Nov. 1

 President Donald Trump said 25% duties on medium- and heavy-duty trucks would begin Nov. 1, the latest expansion of his tariff regime aimed at protecting domestic industries.

The proposal has been subject to an intense lobbying campaign by Detroit’s legacy automakers. Trump originally said last month that heavy-duty truck levies would start Oct. 1, but that timeline slipped as officials heard appeals from companies concerned about the impact.

“Beginning November 1st, 2025, all Medium and Heavy Duty Trucks coming into the United States from other Countries will be Tariffed at the Rate of 25%,” the president posted Monday, without offering further details.

Trump’s announcement is tied to a probe launched in April by the US Commerce Department into heavy truck imports. That investigation, conducted under Section 232 of the Trade Expansion Act, allows for the imposition of import taxes on goods deemed critical to national security.

The probe focused on medium- and heavy-duty trucks weighing more than 10,000 pounds as well as parts, with the Commerce Department stating that a “small number” of foreign suppliers made up the bulk of US imports due to “predatory trade practices.”

The duties threaten an industry already feeling impacts from tariffs on steel and aluminum as well as tighter environmental regulations. New levies on imports could raise prices on vehicles used in a variety of sectors, including shipping, construction and municipal services.

Stellantis NV has urged the administration to waive or soften charges that could hit medium-duty Ram pickups the company makes in Mexico, according to people familiar with the matter. Rivals General Motors Co. and Ford Motor Co. have pushed back on the request, saying it would give Stellantis a cost advantage over US-assembled trucks that contain imported parts already subject to tariffs, the people said.

But proponents of the move say it will help strengthen domestic manufacturing. Trump, in a social media post last week announcing the tariffs, cast them as necessary to “protect our Great Heavy Truck Manufacturers from unfair outside competition.”

Trump’s planned tariffs on imported heavy trucks “are a huge win for American workers and great US manufacturers,” Nick Iacovella of the Coalition for a Prosperous America, a protectionist group, said after Trump’s initial announcement. “This action will strengthen this vital sector and protect it from unfair foreign competition.”

About 245,000 medium- and heavy-duty trucks were imported to the US last year, a trade flow worth more than $20 billion, according to Commerce Department data.

https://finance.yahoo.com/news/trump-says-us-tariffs-heavy-182911805.html

"Civil War Rematch"!? Chi Mayor's "ICE-Free Zones" After Abandoning Border Agents Under Attack

 Chicago Mayor Brandon Johnson signed an executive order Monday blocking federal immigration agents from using city-owned property for immigration enforcement operations - just one day after we learned that the city 'waved off' cops responding to a vehicle-ramming attack on Border Patrol agents over the weekend.

Chicago Mayor Brandon Johnson has rejected President Donald Trump's plan to deploy National Guard troops to Chicago. (Kamil Krazaczynski/Getty Images)

Johnson has established "ICE-free zones," referring to US Immigration and Customs Enforcement (ICE) - as part of his 'Protecting Chicago Initiative.'

"Today, we are signing an executive order aimed at reining in this out-of-control administration," Johnson said during a Monday press conference. "The order establishes ICE-free zones. That means that city property and unwilling private businesses will no longer serve as staging grounds for these raids."

"The Trump administration must end the war on Chicago," Johnson continued. "The Trump administration must end this war against Americans. The Trump administration must end its attempt to dismantle our democracy."

Johnson has directed Chicago agencies and departments to identify spaces within the next five days that have been targeted during ICE raids and post a clear message to federal immigration officers that the city-owned property would not be used for immigration enforcement, including as a staging area, processing location or operations base. -Fox News

The move follows a Monday lawsuit from Gov. JB Pritzker attempting to block the Trump administration from deploying National Guard troops in Chicago. 

Johnson accused the "extreme right" of refusing to accept the results of the Civil War (!?) when slavery - a Democrat thing - was abolished. 

"They have repeatedly called for a rematch, but in the coming weeks, we will use this opportunity to build greater resistance. Chicagoans are clear that militarizing our troops in our city as justification to further escalate a war in Chicago will not be tolerated," he said.

"The right wing in this country wants a rematch of the Civil War," Johnson continued. 

Johnson said that Chicago would "not tolerate ICE agents violating our residents’ constitutional rights," or the Trump administration's "disregard" for state and local authority, Fox News reports. 

"With this executive order, Chicago stands firm in protecting the constitutional rights of our residents and immigrant communities and upholding our democracy," he continued, adding "If the federal government violates this executive order, we will take them to court." 

On Sunday, Pritzker said that he would refuse to comply with the Trump administration's "ultimatum" to deploy Illinois National Guard troops - calling it "absolutely outrageous and unamerican." 

"We must now start calling this what it is: Trump’s invasion," Pritzker continued. 

After Pritzker refused to deploy Illinois troops, Texas Gov. Greg Abbott authorized Trump to use 400 Texas National Guard members for deployment in Illinois and Oregon. 

https://www.zerohedge.com/political/chicago-establishes-ice-free-zones-after-abandoning-border-agents-under-attack-calls

'40 alternative economic reports to utilize during the shutdown'

 Apollo Global Chief Economist Torsten Slok identified 40 economic reports from private data sources that investors can use to gauge the economy during the government shutdown.

The shutdown is expected to last 21 days now, according to prediction market Kalshi.

The reports are:

Consumer spending

1.  OpenTable daily data for restaurant bookings

2.  Bloomberg daily data for debit card transactions

3.  Redbook weekly data for same-store retail sales

4.  Federal Reserve weekly data for retail sales (Chicago Advance Retail Trade Summary)

5.  STR weekly data for hotel demand (revenue per available room, average daily rate, occupancy rate)

6.  The Broadway League weekly data on show attendance

7.  Boxofficemojo.com weekly movie theatre visits

8.  Statue of Liberty visits from irma.nps.gov

9.  US airport arrivals from Customs and Border Protection (CBP)

10. Foreign tourist arrivals from the National Travel and Tourism Office

11. Las Vegas tourism and room nights occupied from Bloomberg

Labor market

1.  ADP non-farm payrolls

2.  Indeed daily job postings

3.  American Staffing Association weekly temp worker staffing index

4.  Challenger, Gray & Christmas announced job cuts (total and government)

Inflation

1.  US inflation swaps from Bloomberg

2.  Imported vs domestic goods prices based on tracking the short-run price impact of U.S. tariffs

3.  Price of goods by country of origin (Canada, Mexico, China, US)

4.  Prices of goods affected by tariffs

5.  WCI weekly container freight rates

6.  National Federation of Independent Business (NFIB) data on plans to raise selling prices

7.  Zillow, Apartment List, and BLS New Tenant Rent Index indicators of housing inflation

8.  University of Michigan survey on short-run and long-run inflation expectations

9.  Federal Reserve Bank of New York survey of consumer inflation expectations

Housing

1.  University of Michigan and National Association of Home Builders data on homebuyer and homebuilder confidence

2.  National Association of Home Builders data on traffic of prospective homebuyers

3.  Redfin data on median days on market for homes for sale

4.  Redfin data on new residential listings

5.  Mortgage Bankers Association (MBA) purchase index

6.  University of Michigan survey on expected change in home values

Production

1.  Federal Reserve and other surveys on corporate capex spending plans

2.  Federal Reserve and Institute for Supply Management (ISM) manufacturing survey on new orders outlook

3.  ISM Purchasing Managers' Index for manufacturing and services

4.  Economic Policy Uncertainty index for trade policy

Consumer sentiment

1.  Conference Board data on consumer expectations for business conditions

2.  Federal Reserve Bank of New York data on job finding expectations

Financial conditions

1.  Bloomberg United States Financial Conditions Index

2.  Bloomberg data on weekly bankruptcy filings for companies with over $50 million in liabilities

3.  The American Bankruptcy Institute data on Chapter 11 commercial bankruptcy filings

4.  Federal Reserve data on weekly loan growth for all commercial banks

https://www.msn.com/en-us/money/markets/40-alternative-economic-reports-to-utilize-during-the-shutdown/ar-AA1NUaio

'Top 5 Biotech Stocks Big Pharma Could Buy Next'

 Companies with Notable Technologies or Pipelines:

• Halozyme Therapeutics (HALO): 

  Known for its Enhanze technology, which allows for subcutaneous (under-the-skin) injections instead of intravenous ones, making treatments more patient-friendly. 
• BioNTech (BNTX): 

  A leader in mRNA technology, the company is also developing vaccines and immunotherapies for a range of diseases, including HIV and tuberculosis. 
• Recursion Pharmaceuticals (RXRX): 

  Uses artificial intelligence (AI) and machine learning to discover and develop drugs, focusing on high-growth potential areas. 
• Axsome Therapeutics (AXSM): 

  Focuses on developing novel therapies for central nervous system disorders, a significant and growing therapeutic area. 
• Exelixis (EXEL): 

  Specializes in the biotechnology and pharmaceutical industry, with a strong focus on developing treatments for cancer. 

https://seekingalpha.com/article/4828107-my-top-5-biotech-stocks-big-pharma-could-buy-next

Details Leak On OpenAI's Secretive Wearable Device, Plagued By Major Issues

 A Financial Times investigation reveals that OpenAI's ambitious wearable AI project, created in partnership with renowned designer Jony Ive, whose work defined Apple's aesthetic for decades, is encountering substantial roadblocks as it attempts to bring the concept to market. Making dystopian AI wearables is harder than it looks.

Former Apple designer Jony Ive and OpenAI CEO Sam Altman (Lia Toby/BFC/Getty Images, Nathan Howard/Bloomberg via Getty Images) 

The device takes an unconventional approach by eliminating screens entirely, instead packaging cameras, microphones, and speakers into a pocket-sized format comparable to contemporary smartphones. Conceived as a creepy ever-present digital partner, it would passively collect information from its surroundings to facilitate ongoing dialogue with users, echoing the design philosophy behind Humane's AI Pin, which, if you recall, didn't exactly set the world on fire.

Beyond keeping details under wraps, OpenAI is wrestling with fundamental technical and design dilemmas. Despite securing massive funding rounds that would make a small nation jealous, the company faces computational constraints that limit the device's capabilities. More unexpectedly, internal debates over the assistant's behavioral characteristics have become a major sticking point. Engineers are caught in a delicate balancing act: the device must offer meaningful input for daily decisions without becoming that insufferably chipper friend who won't stop offering unsolicited advice.

This personality calibration problem isn't new territory for OpenAI. Earlier iterations of its AI models developed reputations for being excessively agreeable. The AI giant also worries about scenarios where the assistant enters repetitive loops during routine activities, which would be about as useful as a GPS that keeps recalculating the same route.

To make matters worse, legal complications further cloud the project's prospects. In June, iyO, an audio technology startup backed by Google, filed a trademark lawsuit challenging OpenAI's use of the "io" branding after the company's $6.5 billion acquisition of Ive's startup in May 2025. The plaintiff argues that "io"—shorthand for "input/output"—creates consumer confusion with its own "audio computer" earpiece product, particularly given that OpenAI leadership, including Sam Altman, had previously examined iyO's technology firsthand.

Awkward.

A federal judge has since issued a temporary restraining order compelling OpenAI to scrub all "io" references from public-facing platforms and marketing content. OpenAI dismisses the lawsuit as baseless and insists the legal dispute won't derail either the acquisition or ongoing product development.

We'll see about that.

https://www.zerohedge.com/technology/details-leak-openais-secretive-wearable-device-plagued-major-issues